The FDA has approved Roivant’s oral JAK inhibitor brepocitinib for dermatomyositis, launching the drug as Lisraya for the rare autoimmune condition. The approval marks Roivant’s first major U.S. regulatory win in dermatomyositis and is positioned as a potentially large commercial opportunity given the current reliance on high-dose steroids and other broad immune-suppressing regimens. Dermatomyositis—characterized by muscle weakness and painful skin rash—affects an estimated 40,000 to 70,000 people in the U.S. The approval gives clinicians a first-in-class oral option that targets disease pathways more specifically than steroids, which remain the standard of care. For Roivant and its subsidiary Priovant, the nod also signals momentum for the company’s hub-and-spoke model, where platform investments can support multiple asset expansions and faster commercial rollout when regulatory milestones are hit.